11 months ago
Biocon's Yesafili for retinal diseases receives public funding in Ontario
Biocon Biologics has announced that their medicine Yesafili, which helps with eye problems, will now be paid for by the government in Ontario, Canada.
Yesafili is similar to another medicine called Eylea.
This means people with eye conditions like macular degeneration will find it easier to get the medicine.
This change will make the treatment more affordable and save money for the healthcare system.
Studies have shown that Yesafili works just as well as Eylea.
The medication is given in a specific dose and will be available in both vials and prefilled syringes.
Yesafili is the first of its kind approved by Health Canada.
Biocon Biologics Ltd's Yesafili is now publicly funded in Ontario.
Yesafili is a biosimilar to Eylea, used to treat retinal diseases.
The funding covers both vial and prefilled syringe presentations.
It's approved for conditions like wet AMD and diabetic macular oedema.
Ontario is the first Canadian province to publicly fund this biosimilar.
- Who
- Biocon Biologics Ltd (BBL)
- What
- Yesafili (aflibercept), a biosimilar to Eylea, is now publicly funded in Ontario for retinal diseases
- Where
- Ontario, Canada
- When
- Announced recently (September 18)
- Why
- To increase accessibility to treatment for retinal diseases and lower costs for patients and the healthcare system.
Key facts
- Company
- Biocon Biologics Ltd (BBL)
- Medication
- Yesafili (aflibercept)
- Purpose
- Treatment of retinal diseases
- Approved for
- Neovascular (wet) age-related macular degeneration (AMD), diabetic macular oedema (DME), visual impairment due to macular oedema secondary to CRVO/BRVO, and myopic choroidal neovascularisation (myopic CNV)
- Location of Funding
- Ontario, Canada
- Dosage
- 2 mg/0.05 ml
Quotes
Ramy Ayad
Head of Canada at Biocon Biologics
“Ontario's public funding of Yesafili, Canada’s first Eylea biosimilar and our seventh biosimilar in the country, underscores our commitment to expanding access to biologics and building a sustainable biosimilars environment.”
CNBC TV 18
“Yesafili provides a high-quality, affordable option, removing significant cost barriers for patients and delivering substantial savings to the healthcare system”
CNBC TV 18
